Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 8/20 | 0.54 |
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394331 | 0.82 | NPC1 (0.69) | MAPTPOLBRAB9ANPC1ALDH1A1 | |
| SCHEMBL27540201 | 0.75 | CRHBP (0.50) | MAPTPOLBRAB9ANPC1ALDH1A1 | |
| SCHEMBL6160806 | 0.75 | MAPT (0.50) | MAPTPOLBRAB9ANPC1ALDH1A1 | |
| SCHEMBL6202919 | 0.75 | MEN1 (0.61) | MAPTPOLBALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL26083579 | 0.75 | MEN1 (0.64) | MAPTPOLBRAB9AALDH1A1MEN1 | |
| SCHEMBL11133530 | 0.75 | PKM (0.64) | ALDH1A1SMN1; SMN2ACHEMEN1KMT2A | |
| SCHEMBL6201392 | 0.75 | KMT2A (0.58) | MAPTPOLBALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6321927 | 0.74 | ALOX5 (0.62) | MAPTRAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8064713 | 0.74 | NPC1 (0.62) | MAPTRAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL27597238 | 0.74 | TRPV1 (0.48) | MAPTRAB9ANPC1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339694-B1 | SUBSTITUTED 2-PHENYLAMINOIMIDAZOLINE PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-09-21 | — | — | EP | disclosed |
| EP-1339694-A1 | SUBSTITUTED 2-PHENYLAMINOIMIDAZOLINE PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| US-20020091147-A1 | SUBSTITUTED-PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | SYNTEX (U.S.A.) LLC | 2002-07-11 | — | — | US | disclosed |
| US-6417186-B1 | TREATING PAIN, URINARY TRACT INFECTIONS, INFLAMMATION, RESPIRATORY DISEASE STATES FROM ALLERGIES OR ASTHMA, EDEMA FORMATION OR HYPOTENSIVE VASCULAR DISEASES. | SYNTEX (U.S.A.) LLC | 2002-07-09 | — | — | US | disclosed |
| WO-2002040453-A1 | SUBSTITUTED 2-PHENYLAMINOIMIDAZOLINE PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091147-A1 | SUBSTITUTED-PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | PTGER1, FFAR1, BDKRB1 | MAPT 4409/4885POLB 4440/4885RAB9A 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.